Hemgenix - etranacogene dezaparvovec Hemgenix is indicated for the treatment of severe and moderately severe Haemophilia B (congenital Factor IX deficiency) in adult patients without a history of Factor IX inhibitors. European authorization on: 23/02/2023

Ebvallo - Tabelecleucel Ebvallo is indicated as monotherapy for treatment of adult and paediatric patients 2 years of age and older with relapsed or refractory Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) who have received at least one prior therapy. For solid organ transplant patients, prior therapy includes chemotherapy unless chemotherapy is inappropriate. European authorization on: 16/12/2022

Livmarli - maralixibat chloride Livmarli is indicated for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) 2 months of age and older. European authorization on: 12/12/2022

Mycapssa - octreotide Mycapssa is indicated for maintenance treatment in adult patients with acromegaly who have responded to and tolerated treatment with somatostatin analogues. European authorization on: 05/12/2022

Enjaymo - sutimlimab Enjaymo is indicated for the treatment of haemolytic anaemia in adult patients with cold agglutinin disease (CAD). European authorization on: 23/11/2022